Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib plus fulvestrant in postmenopausal advanced breast cancer
2008-000579-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Event-free survival. Started Oct 2008; status: completed.
02
Drugs
vandetanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-000579-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000579-12.